Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Current Assets: 2012-2024

Historic Current Assets for Ptc Therapeutics (PTCT) over the last 13 years, with Dec 2024 value amounting to $1.4 billion.

  • Ptc Therapeutics' Current Assets rose 56.67% to $2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year increase of 56.67%. This contributed to the annual value of $1.4 billion for FY2024, which is 12.05% up from last year.
  • Per Ptc Therapeutics' latest filing, its Current Assets stood at $1.4 billion for FY2024, which was up 12.05% from $1.2 billion recorded in FY2023.
  • In the past 5 years, Ptc Therapeutics' Current Assets registered a high of $1.4 billion during FY2024, and its lowest value of $693.8 million during FY2022.
  • Moreover, its 3-year median value for Current Assets was $1.2 billion (2023), whereas its average is $1.1 billion.
  • As far as peak fluctuations go, Ptc Therapeutics' Current Assets fell by 27.30% in 2022, and later spiked by 75.65% in 2023.
  • Over the past 5 years, Ptc Therapeutics' Current Assets (Yearly) stood at $1.2 billion in 2020, then declined by 22.52% to $954.4 million in 2021, then fell by 27.30% to $693.8 million in 2022, then soared by 75.65% to $1.2 billion in 2023, then increased by 12.05% to $1.4 billion in 2024.